ABT 📈 Abbott Laboratories - Overview
Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US0028241000
ABT: Pharmaceuticals, Diagnostic Tools, Nutritionals, Medical Devices
Abbott Laboratories is a multinational healthcare company that develops, manufactures, and markets a wide range of healthcare products globally. The company operates through four primary segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Its pharmaceutical offerings include a diverse portfolio of generic medications for treating various conditions, such as pancreatic exocrine insufficiency, irritable bowel syndrome, and hormone replacement therapy, as well as anti-infective medications like clarithromycin and influenza vaccines. Additionally, Abbott provides products that regulate the physiological rhythm of the colon, addressing gastrointestinal health.
The company's diagnostic product portfolio is equally extensive, featuring laboratory and transfusion medicine systems that cater to immunoassay, clinical chemistry, hematology, and transfusion needs. It also offers molecular diagnostics solutions, including polymerase chain reaction instrument systems that automate DNA and RNA extraction, purification, and preparation from patient samples, enabling the detection and measurement of infectious agents. Point-of-care systems, cartridges for testing various blood parameters, rapid diagnostics lateral flow testing products, and molecular point-of-care testing solutions for diseases like HIV, SARS-CoV-2, and influenza are also part of its offerings. Furthermore, Abbott provides cardiometabolic test systems, drug and alcohol testing solutions, remote patient monitoring systems, and consumer self-test systems, along with informatics and automation solutions for laboratories to enhance efficiency and accuracy.
Abbott's nutritional products cater to both pediatric and adult needs, providing essential nutrients for growth and maintenance of health. The company is also a significant player in the medical devices sector, particularly in the treatment of cardiovascular diseases, offering rhythm management, electrophysiology, heart failure, vascular, and structural heart devices. Its diabetes care products include glucose and blood glucose monitoring systems, which are crucial for managing diabetes. Additionally, Abbott develops and markets neuromodulation devices designed to manage chronic pain and movement disorders, improving the quality of life for patients with these conditions.
With a rich history dating back to 1888, Abbott Laboratories is headquartered in North Chicago, Illinois. The company's commitment to innovation and its broad spectrum of healthcare products and services position it as a leader in the global healthcare industry. Its presence is felt worldwide, with a significant online presence at https://www.abbott.com, and it is listed on the New York Stock Exchange (NYSE) under the ticker symbol ABT, with the ISIN US0028241000, classified as a common stock under the GICS Sub Industry: Health Care Equipment.
Additional Sources for ABT Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
ABT Stock Overview
Market Cap in USD | 197,971m |
Sector | Healthcare |
Industry | Medical Devices |
GiC Sub-Industry | Health Care Equipment |
IPO / Inception | 1978-01-13 |
ABT Stock Ratings
Growth 5y | 30.7% |
Fundamental | 50.5% |
Dividend | 64.7% |
Rel. Strength Industry | 313 |
Analysts | 4.22/5 |
Fair Price Momentum | 106.90 USD |
Fair Price DCF | 96.75 USD |
ABT Dividends
Dividend Yield 12m | 1.95% |
Yield on Cost 5y | 2.78% |
Annual Growth 5y | 8.85% |
Payout Consistency | 96.7% |
ABT Growth Ratios
Growth Correlation 3m | -39.9% |
Growth Correlation 12m | 35% |
Growth Correlation 5y | 31.1% |
CAGR 5y | 7.36% |
CAGR/Mean DD 5y | 0.51 |
Sharpe Ratio 12m | -0.02 |
Alpha | -19.07 |
Beta | 0.76 |
Volatility | 17.84% |
Current Volume | 6037.2k |
Average Volume 20d | 4849.1k |
As of January 07, 2025, the stock is trading at USD 113.04 with a total of 6,037,209 shares traded.
Over the past week, the price has changed by +0.21%, over one month by -2.21%, over three months by +0.19% and over the past year by +2.58%.
Partly, yes. Based on ValueRay Fundamental Analyses, Abbott Laboratories (NYSE:ABT) is currently (January 2025) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 50.50 and therefor a somewhat positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of ABT as of January 2025 is 106.90. This means that ABT is currently overvalued and has a potential downside of -5.43%.
Abbott Laboratories has received a consensus analysts rating of 4.22. Therefor, it is recommend to buy ABT.
- Strong Buy: 13
- Buy: 8
- Hold: 5
- Sell: 1
- Strong Sell: 0
According to ValueRays Forecast Model, ABT Abbott Laboratories will be worth about 117.5 in January 2026. The stock is currently trading at 113.04. This means that the stock has a potential upside of +3.95%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 129.9 | 14.9% |
Analysts Target Price | 110.7 | -2.1% |
ValueRay Target Price | 117.5 | 4% |